Skip to content

Palvella Therapeutics

US · PVLA #2822 by market cap Listed 1970
142.85 -2.92 -2.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.4 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
108.88% -0.40pp
Institutions
244 +1
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund64.34%
Hedge Fund19.60%
VC/PE Fund14.72%
Individual/Insider7.70%
Private Company4.18%
Public Company3.23%
Sovereign Wealth Fund1.81%
Insurance Company0.38%
Endowment Fund0.31%
Government Pension Fund0.26%

Top holders as of 2026-06-30

Montanova Capital, LLC 7.77% · 1.14M sh
Jennison Associates LLC 7.54% · 1.10M sh
BlackRock 6.77% · 989.69K sh
Frazier Life Sciences Management, LP 6.04% · 882.40K sh
Wesley Kaupinen 5.65% · 825.82K sh
First Light Asset Management, LLC 5.28% · 771.90K sh
BVF Partners L.P. 4.60% · 672.79K sh
T. Rowe Price Group, Inc. 4.37% · 638.87K sh
State Street Global Advisors 4.27% · 624.88K sh
Integrated Financial Group 3.83% · 559.95K sh
Vanguard Capital Management, LLC 4.08% · 587.79K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 29 buys · 20 sells

NameRoleStake
Wesley Kaupinen Chief Executive Officer 5.65%
George Jenkins Independent Chairperson 0.91%
Todd Davis Independent Director 0.77%
Elaine Heron Independent Director 0.37%
Matthew Korenberg CFO, Corporate Secretary & Treasurer 0.01%
Christopher Kiritsy Independent Director 0.00%
BVF Partners L.P. -- --
Tadd Wessel Independent Director --
John Doux Independent Director --
Matthew Pauls Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-10 Jeffrey Martini Chief Scientific Officer Derivative Exercise and Sale -12,500 $7.53–172.12
2026-11-09 Jeffrey Martini Chief Scientific Officer Intent to Sell (Form 144) -50,000 $174.08
2026-10-20 Kathleen Goin Chief Operating Officer Derivative Exercise and Sale -4,313 $7.14–126.19
2026-10-13 George Jenkins Independent Chairperson Automatic Disposition -27,500 $121.14–136.44
2026-10-12 George Jenkins Independent Chairperson Intent to Sell (Form 144) -27,500 $134.38
2026-09-15 Kathleen Goin Chief Operating Officer Derivative Exercise and Sale -4,302 $7.14–153.24
2026-09-14 George Jenkins Independent Chairperson Automatic Disposition -27,500 $149.38–153.10
2026-09-10 George Jenkins Independent Chairperson Intent to Sell (Form 144) -27,500 $150.39
2026-09-01 Christopher Kiritsy Independent Director Derivative Exercise and Sale -313 $127.20–157.00
2026-08-18 Kathleen Goin Chief Operating Officer Derivative Exercise and Sale -4,302 $7.14–156.77
2026-07-14 Kathleen Goin Chief Operating Officer Derivative Exercise and Sale -4,302 $7.14–150.25
2026-06-28 Matthew Pauls Director Other Derivative Acquisition +6,000 $154.84
2026-06-16 Kathleen Goin Chief Operating Officer Derivative Exercise and Sale -4,302 $7.14–112.23
2026-06-11 Matthew Korenberg CFO, Corporate Secretary & Treasurer Derivative Exercise and Retained +1,000 $13.60
2026-06-09 George Jenkins Independent Chairperson Other Derivative Acquisition +3,000 $102.19
2026-06-09 Elaine Heron Independent Director Other Derivative Acquisition +3,000 $102.19
2026-06-09 Todd Davis Independent Director Other Derivative Acquisition +3,000 $102.19
2026-06-09 Christopher Kiritsy Independent Director Other Derivative Acquisition +3,000 $102.19
2026-06-09 Tadd Wessel Independent Director Other Derivative Acquisition +3,000 $102.19
2026-06-09 John Doux Independent Director Other Derivative Acquisition +3,000 $102.19

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Palvella Therapeutics discussion 0 comments

Add a comment